Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.46 |
| ▸ | TTPA | P49638 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14168733 | 0.86 | MEN1 (0.64) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL18883312 | 0.84 | GSTO1 (0.77) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL8420875 | 0.84 | PSEN1 (0.65) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL17991478 | 0.83 | GSTO1 (0.70) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL14266510 | 0.82 | GSTO1 (0.48) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL24435912 | 0.81 | GSTO1 (0.84) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL12716118 | 0.81 | GSTO1 (0.84) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL13355948 | 0.79 | PSEN1 (0.53) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL3106018 | 0.76 | PTPN1 (0.61) | GSTO1PTPN1MEN1KMT2APDE4A | |
| SCHEMBL7330589 | 0.76 | MEN1 (0.58) | GSTO1PTPN1MEN1KMT2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070128289-A1 | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases | CORDIS CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070128289-A1 | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases | PTGES, PTGIS, CACNG1 | GSTO1 1480/4885PTPN1 4128/4885MEN1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.